Ingenito Gary's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Jun 7, 2024
- Accession no.
- 0001161697-24-000256
- Filed
- Jun 7, 2024
- Trade date
- Jun 5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.29M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ingenito GaryCIK 0001279473 | Officer (Chief Med. & Reg. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +80,000 | $4.01 | +$320,800 | 131,391 | Direct | |
| Jun 5, 2024 | Common stock, par value $0.001 per share | SSaleDisposed | −80,000 | $16.16F1,F2 | −$1,292,800 | 51,391 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Common Stock | MOption exerciseDisposed | −80,000 | $0.00 | $0 | 1,050,575 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Dr. Ingenito sold the shares on the open market to for personal reasons and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a result of any disagreement with the Company.
Referenced by the price of 1 transaction in Table I.
- F2
Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $16.11 to $16.27 per share.
Referenced by the price of 1 transaction in Table I.